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Pharmacovigilance of Biosimilars 
Abstract 
In lieu of an abstract, here is the article's first paragraph: 
Biotech industry forms the backbone of the current pharmaceutical products. Seven out of top ten 
anticipated drugs of the industry in 2014 will be biologics [1]. Considering the fast pace growth of the 
biotechnological products, there is a parallel demand of biosimilars. As defined by FDA, “A biosimilar is a 
biological product that is highly similar to a U.S.-licensed reference biological product notwithstanding 
minor differences in clinically inactive components, and for which there are no clinically meaningful 
differences between the biological product and the reference product in terms of the safety, purity, and 
potency of the product” [2]. Thus these biosimilar products become affordable alternatives to several 
biotechnological products, which are going off-patent. Along with the benefit of cost-effective therapy and 
scope of further research leading to the possibility of bio-superiors, biosimilars have led to formation of a 
whole new branch of biotech industry. However, there are various other concerns that require these 
biosimilars to be monitored closely. 
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Biotech industry forms the backbone of the current pharmaceutical 
products. Seven out of top ten anticipated drugs of the industry in 
2014 will be biologics [1]. Considering the fast pace growth of the 
biotechnological products, there is a parallel demand of biosimilars. 
As defined by FDA, “A biosimilar is a biological product that is highly 
similar to a U.S.-licensed reference biological product notwithstanding 
minor differences in clinically inactive components, and for which 
there are no clinically meaningful differences between the biological 
product and the reference product in terms of the safety, purity, and 
potency of the product” [2]. Thus these biosimilar products become 
affordable alternatives to several biotechnological products, which are 
going off-patent. Along with the benefit of cost-effective therapy and 
scope of further research leading to the possibility of bio-superiors, 
biosimilars have led to formation of a whole new branch of biotech 
industry. However, there are various other concerns that require these 
biosimilars to be monitored closely. 
The European Medicines Agency (EMEA) issued a guideline on 
“similar biological medicinal products” in October 2005 and since then 
14 biosimilar products have been approved by EMA for the European 
market. These include biologics of three major classes: human growth 
hormone, granulocyte colony-stimulating factor and erythropoietin 
[3]. Considering the need for biosimilars for the current market, U.S. 
FDA has also issued draft guidance, recently in 2010, in an attempt to 
provide licensure pathway for biosimilars. The guidance aims to assure 
the safety, purity and potency of these biosimilars before approval. 
Unlike the generic drugs for small molecules, the biosimilars 
will undergo stringent regulatory processes. As the biosimilars can 
be manufactured in multiple different ways and have human/animal 
origin, they can yield to the formation of biological product with 
similar efficacy but varied adverse effects to the reference. Thus, unlike 
small molecule generics, a biosimilar approval requires clinical studies 
to ensure that small manufacturing changes have not altered the 
therapeutic efficacy of the biological drug. Further, pharmacovigilance 
allows monitoring of adverse effects associated with a particular 
marketed biosimilar [4].
World Health Organization (WHO) defines pharmacovigilance 
as “the science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other drug-
related problem” [5]. Once a drug is released in the market by FDA, 
it is monitored for its safety profile. Further, the adverse effects caused 
by the drug are reported to generate post-marketing surveillance data. 
Post-marketing pharmacovigilance becomes even more critical in 
case of biosimilars as there is limited information available regarding 
them. Additionally, the effect of such biosimilars on diverse patient 
populations with respect to the dosage and duration of therapy needs to 
be closely monitored. Due to these reasons, biosimilars are required to 
undergo same pharmacovigilance regulations as its reference product. 
Thus biosimilars approved by EMEA are required to submit a risk 
management plan (RMP) along with the marketing application and 
have to provide regular safety update reports after the product is in the 
market. The RMP includes the safety profile of the drug and proposes 
the prospective pharmacovigilance studies [6]. 
Currently, the approved biosimilars of European market are 
under strict pharmacovigilance to assure patient safety. Ebbers et 
al. [7] reports various pharmacovigilance activities that have been 
conducted to monitor the safety of such approved biosimilars. These 
efforts includes cohort studies and surveys to monitor the adverse 
effects of erythropoietin biosimilars, pharmacovigilance programs and 
safety follow-up for long term data regarding the use of granulocyte 
colony-stimulating factor and a check on immunogenicity data for 
human growth hormone administered to the younger population 
[7]. Along with these studies spontaneous monitoring of the adverse 
effects serves to be useful. Spontaneous reports originating from the 
healthcare providers assist in identifying the biologic responsible for 
it, target patient population, severity of the adverse effect and the 
need of intervention. Overall, these surveillance studies are capable 
of generating information that will not only be useful for the patient 
population in Europe but will also provide supporting data to the 
scientists in other countries like the U.S. where several biotech/
pharmaceutical companies plan to venture in the field of biosimilars. 
In conclusion, pharmacovigilance is an integral part of biosimilar 
approval due to the fact that these biologics are unlike small 
molecule generics. Pharmacovigilance studies will continue to assist 
biotechnological companies to bring safe and efficacious biologics to 
the market as the information pool grows regarding the safety profile of 
some of the approved biologics.
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